These results demonstrate that the 1,157-bp mid-Myo15 promoter is a strong and HC-specific promoter that can be further used in gene therapy of hereditary hearing loss caused by other genes and for the clinical translation of OTOF gene therapy. Here, MYO15A is linked to hearing loss disorder.